Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

Questionnaires in Assessing Attitudes About Legalization of Marijuana Use in Participants With Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03360799
Recruitment Status : Completed
First Posted : December 4, 2017
Last Update Posted : August 30, 2019
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
M.D. Anderson Cancer Center

Brief Summary:
This trial studies attitudes about legalization of marijuana use in participants with cancer. Questionnaires may help doctors to learn about and compare the attitudes that patients in non-legalized and legalized states have towards the legalization of medical marijuana.

Condition or disease Intervention/treatment
Malignant Neoplasm Other: Questionnaire Administration

Detailed Description:

PRIMARY OBJECTIVES:

I. To compare the proportion of cancer patients' who have a positive attitude about legalizing marijuana for medical purposes between those in a legalized versus (vs.) a non-legalized state.

SECONDARY OBJECTIVES:

I. To evaluate the association of cancer patients' belief in the usefulness of medical marijuana in their state of residency (Texas versus Arizona).

II. To examine the association of demographic, physical and psychosocial characteristics of patients and their perception of medical marijuana.

III. To examine the preference of patients for treatment of pain, anxiety and depression between medical marijuana vs. opioids, anti-anxiety and anti-depressant medications.

IV. To examine the association of media to perception of use of medical marijuana.

V. To evaluate the association of cancer patients' attitude about legalizing marijuana for medical purposes vs. recreational purposes.

VI. To examine the association of patients who have used marijuana for certain medical conditions/symptoms and their belief of how it has affected that condition/symptom.

VII. To compare demographic, physical and psychosocial characteristics of patients who have used marijuana for medical purposes.

VIII. To compare demographic, physical and psychosocial characteristics of patients who have used marijuana for non-medical purposes. IX. To compare demographic, physical and psychosocial characteristics of patients who believe marijuana is useful for medical reasons.

OUTLINE:

Participants complete 5 questionnaires.

Layout table for study information
Study Type : Observational
Actual Enrollment : 103 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Comparison of the Attitudes About Legalization of Marijuana Use for Medical Purposes by Cancer Patients in Two Cancer Centers Located in a Legalized and a Non-Legalized State
Actual Study Start Date : November 17, 2017
Actual Primary Completion Date : August 26, 2019
Actual Study Completion Date : August 26, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Marijuana

Group/Cohort Intervention/treatment
Observational (questionnaire)
Participants complete 5 questionnaires.
Other: Questionnaire Administration
Complete questionnaires




Primary Outcome Measures :
  1. Positive attitude regarding the legalization of medical marijuana for medical purposes [ Time Frame: Up to 1 year ]
    Will be defined as answering "Completely Agree" or "Slightly Agree" to the question 1 in Marijuana Survey for Patients. The number of subjects with positive attitude towards legalizing medical marijuana will be compared between patients from Texas and Arizona States using one-sided Fisher's exact test or chi-squared test, whichever appropriate. A logistic model will be used to assess the effect of state of residency, adjusting for other covariates such as gender, age, race, etc. Will employ inverse probability of state weighting using the propensity score on all patients to estimate the difference in attitudes of marijuana use between the states. In the weighted sample, will also compute the standardized differences to evaluate the balance of baseline covariates between the two states. The propensity score model may be adjusted to further minimize some of the residual difference in the distribution of the baseline covariates between the two states.


Secondary Outcome Measures :
  1. Participants' belief in the usefulness of medical marijuana between those who are residents of Texas versus Arizona [ Time Frame: Up to 1 year ]
    The proportion of patients with positive belief will be reported with a 95% confidence interval. Fisher's exact test will be applied to compare the proportion between residents of two states.

  2. Perception of medical marijuana [ Time Frame: Up to 1 year ]
    Will evaluate the association of demographical, physical, and psychosocial characteristics of patients and their perception of medical marijuana. In order to address this objective, all the specified characteristics will be summarized by descriptive statistics based on patients' perception of medical marijuana (positive or negative attitude); chi-square (or Fisher's exact) test and Wilcoxon rank sum test may be applied to test the associations for categorical and continuous variables, respectively. Logistic regression model may be utilized to evaluate the association of patients' characteristics with their perception of medical marijuana. Summarized reports of all other questions regarding the preference of patients for treatment of pain, anxiety and depression between medical marijuana versus opioids, anti-anxiety, anti-depressant medications, as well as the perception of impact of media on patient's preference in the Marijuana Survey for Patients will be provided.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Participants with cancer seen by the Palliative Care team at Banner MD Anderson or University of Texas (UT) MD Anderson
Criteria

Inclusion Criteria:

  • Patients (inpatient or outpatient) seen by the Palliative Care team at Banner MD Anderson or UT MD Anderson
  • Patients able to speak and read English
  • Patients enrolled in each site must be a resident of the state where that site is located (e.g. if a patient is enrolled at UT MD Anderson Cancer Center [MDACC], they should be resident of the state of Texas)
  • Patients should have a cancer diagnosis

Exclusion Criteria:

  • Patients who are not able to speak or read English
  • Altered mental status as determined by the interviewer based on the ability to understand the nature of the study and consent process

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03360799


Locations
Layout table for location information
United States, Arizona
Banner MD Anderson Cancer Center
Gilbert, Arizona, United States, 85234
United States, Texas
M D Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: Kimberson C Tanco M.D. Anderson Cancer Center

Additional Information:
Layout table for additonal information
Responsible Party: M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier: NCT03360799    
Other Study ID Numbers: 2017-0568
NCI-2018-01026 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
2017-0568 ( Other Identifier: M D Anderson Cancer Center )
P30CA016672 ( U.S. NIH Grant/Contract )
First Posted: December 4, 2017    Key Record Dates
Last Update Posted: August 30, 2019
Last Verified: August 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Marijuana Use
Neoplasms
Substance-Related Disorders
Mental Disorders